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Abstract
Background: In hereditary breast and ovarian cancer (HBOC), family communication of genetic test results is essential for
cascade genetic screening, that is, identifying and testing blood relatives of known mutation carriers to determine whether they
also carry the pathogenic variant, and to propose preventive and clinical management options. However, up to 50% of blood
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relatives are unaware of relevant genetic information, suggesting that potential benefits of genetic testing are not communicated
effectively within family networks. Technology can facilitate communication and genetic education within HBOC families.
Objective: The aims of this study are to develop the K-CASCADE (Korean–Cancer Predisposition Cascade Genetic Testing)
cohort in Korea by expanding an infrastructure developed by the CASCADE (Cancer Predisposition Cascade Genetic Testing)
Consortium in Switzerland; develop a digital health intervention to support the communication of cancer predisposition for Swiss
and Korean HBOC families, based on linguistic and cultural adaptation of the Family Gene Toolkit; evaluate its efficacy on
primary (family communication of genetic results and cascade testing) and secondary (psychological distress, genetic literacy,
active coping, and decision making) outcomes; and explore its translatability using the reach, effectiveness, adoption,
implementation, and maintenance framework.
Methods: The digital health intervention will be available in French, German, Italian, Korean, and English and can be accessed
via the web, mobile phone, or tablet (ie, device-agnostic). K-CASCADE cohort of Korean HBOC mutation carriers and relatives
will be based on the CASCADE infrastructure. Narrative data collected through individual interviews or mini focus groups from
20 to 24 HBOC family members per linguistic region and 6-10 health care providers involved in genetic services will identify
the local cultures and context, and inform the content of the tailored messages. The efficacy of the digital health intervention
against a comparison website will be assessed in a randomized trial with 104 HBOC mutation carriers (52 in each study arm).
The translatability of the digital health intervention will be assessed using survey data collected from HBOC families and health
care providers.
Results: Funding was received in October 2019. It is projected that data collection will be completed by January 2023 and
results will be published in fall 2023.
Conclusions: This study addresses the continuum of translational research, from developing an international research infrastructure
and adapting an existing digital health intervention to testing its efficacy in a randomized controlled trial and exploring its
translatability using an established framework. Adapting existing interventions, rather than developing new ones, takes advantage
of previous valid experiences without duplicating efforts. Culturally sensitive web-based interventions that enhance family
communication and understanding of genetic cancer risk are timely. This collaboration creates a research infrastructure between
Switzerland and Korea that can be scaled up to cover other hereditary cancer syndromes.
Trial Registration: ClinicalTrials.gov NCT04214210; https://clinicaltrials.gov/ct2/show/NCT04214210 and CRiS KCT0005643;
https://cris.nih.go.kr/cris/
International Registered Report Identifier (IRRID): PRR1-10.2196/26264
(JMIR Res Protoc 2021;10(6):e26264) doi: 10.2196/26264
KEYWORDS
HBOC; proportion of informed at-risk relatives; coping; communicating; decisional conflict; cultural and linguistic adaptation;
implementation; RE-AIM; mobile phone
Introduction
Background
In 2018, there were approximately 2.1 million breast cancer
diagnoses and more than 600,000 associated deaths worldwide
[1,2]. The worldwide average breast cancer incidence is 74.2
per 100,000 women [3], with approximately 25% of cases
occurring in women younger than 50 years and in women with
a family history of cancer [4,5]. Approximately 5%-10% of
breast cancer and 20% of ovarian cancer cases occur due to
germline pathogenic variants associated with hereditary breast
and ovarian cancer (HBOC) syndrome, most commonly
observed in the BRCA-1 and BRCA-2 genes (hereafter BRCA).
The prevalence of germline pathogenic variants differs among
ethnic groups [6]; however, Switzerland and Korea have a
similar prevalence ranging from 23% to 26% [7,8].
The availability of genetic services (counseling and testing) for
actionable hereditary cancer syndromes such as HBOC enables
population-level cancer prevention [9]. Blood relatives of HBOC
cases have a 12.5%-50% probability of inheriting the same
pathogenic variant and can be tested with 100% accuracy.
Chemoprevention, prophylactic surgery, and intensive
surveillance can lower cancer risks for relatives who test
positive, whereas those who test negative are excluded from
these interventions [10-12]. The Centers for Disease Control
and Prevention Office for Public Health Genomics recommend
genetic testing in cancer-free individuals with a known HBOC
family history and in patients with cancer who have strong
indications of HBOC syndrome (eg, ovarian cancer) [13].
Cascade genetic screening is a systematic effort to identify and
test all blood relatives of HBOC cases to determine whether
they also carry the same pathogenic variant [10]. The
CASCADE (Cancer Predisposition Cascade Genetic Testing)
Consortium in Switzerland promotes cascade genetic screening
for HBOC [14,15], whereas the Korean Hereditary Breast
Cancer (KOHBRA) network identifies the prevalence of
HBOC-associated pathogenic variants in the Korean population
[16,17].
Despite calls to action for HBOC cascade genetic testing, there
are systemic barriers to its implementation. Privacy laws
worldwide, including Switzerland and Korea, restrict health
care providers from revealing genetic information to anyone
except the tested individual, who has the right not to disclose
this information, despite implications for relatives’ health
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[18-20]. The potential benefits of genetic testing are not being
effectively communicated through family networks, leading to
more than 50% of at-risk individuals not using genetic services
and not receiving important information from a credible source
[21-23]. Second-degree and male relatives, those living further
away, and those with an estranged relationship with the mutation
carrier are most likely not to be informed about genetic testing
[24,25]. Despite these difficulties, a family-based approach in
communicating hereditary cancer risk is advantageous because
it may reach relatives through the social bonds and functions
already existing within the family network, and it is not limited
to those in contact with the health care system [26].
Interventions that support mutation carriers during the disclosure
of genetic test results can reduce psychological distress and
provide relatives with accurate and credible information about
cascade genetic testing. Technology-enabled education is not
inferior to face-to-face genetic consultations [27,28], but it
increases access to services and cost-effectiveness [29-32]. The
Family Gene Toolkit [33] is a web-based intervention designed
to increase prerequisites for HBOC cascade testing, that is,
active coping, open family communication, and informed
decision making. The prototype Family Gene Toolkit was tested
in the United States for acceptability and patient satisfaction
with excellent results, confirming its value for these families.
However, it is not available in other linguistic and cultural
contexts. Adapting existing interventions, rather than developing
new ones, takes advantage of the previous valid experiences
without duplicating efforts.
In summary, HBOC cascade genetic testing, meaning the
identification and testing of blood relatives, provides risk
management options for those with a germline pathogenic
variant and excludes confirmed noncarriers (ie, negative testing
when there is a known pathogenic variant in the family) from
intensive surveillance and risk-reducing measures. Due to
privacy laws, mutation carriers have the sole responsibility to
inform blood relatives about genetic test results and advocate
for genetic services. Digital health platforms can support
mutation carriers during the disclosure process and provide
relatives with accurate and credible information.
Objectives
The DIALOGUE study will build a bilateral research
infrastructure to support collaboration and multidisciplinary
initiatives around HBOC in Switzerland and Korea. The specific
aims are to develop the K-CASCADE (Korean–Cancer
Predisposition Cascade Genetic Testing) cohort in Korea by
expanding an existing research infrastructure developed by the
CASCADE Consortium in Switzerland; develop a digital health
intervention to support open communication and cascade genetic
testing in HBOC families, based on the linguistic and cultural
adaptation of the Family Gene Toolkit; evaluate the efficacy of
the digital health intervention on primary (communication of
genetic test results to relatives and cascade genetic testing) and
secondary (psychological distress, genetic literacy, coping, and
decision making) outcomes; and explore the translatability of
the platform using the reach, effectiveness, adoption,
implementation, and maintenance (RE-AIM) framework.
Methods
Design
The DIALOGUE study will use a cohort design to establish the
K-CASCADE in Korea and a randomized controlled trial (RCT)
design to test the effects of digital health intervention in the
Swiss and Korean contexts. The study will measure clinical and
process outcomes in real-world conditions, including different
settings, participants, and resources [34,35].
Aim 1: Develop the K-CASCADE Cohort
The K-CASCADE cohort will identify and survey mutation
carriers and blood relatives as its archetype, the Swiss
CASCADE cohort, using similar design, assessments, and
procedures for sample identification and data collection [14].
Adult Korean men and women with BRCA pathogenic variants
will be invited to the K-CASCADE cohort. They will also be
asked to invite their first- and second-degree relatives and their
first cousins for cascade genetic screening. Similar to the Swiss
CASCADE, it is envisioned that the K-CASCADE cohort will
include known mutation carriers, untested relatives with
unknown mutation status, and relatives who tested negative for
the pathogenic variant.
Aim 2: Adapt the Digital Health Intervention
The content of the Family Gene Toolkit is driven by theory [36]
and supported by empirical findings [37-41]. It is designed to
address challenges related to the quantity and complexity of
genetic information mutation carriers are asked to communicate
with family members [42,43]. Understanding HBOC (eg,
probability of mutation, prognosis, prevention, and treatment)
and the accuracy of genetic testing are important for decision
making. Inherited cancer risk requires ongoing management
and, thus, active coping with health challenges. Mutation
carriers’personal values and communication skills are important
for the disclosure of genetic cancer risk. The Family Gene
Toolkit embraced the above challenges and included 4 modules
designed to increase knowledge of cancer genetics (module 1),
provide decisional support for genetic testing to untested
relatives (module 2), increase active coping with common
challenges faced by HBOC families (module 3), and provide
skills-building communication training (module 4; Figure 1).
The adapted Family Gene Toolkit will include the 4 original
modules and a fifth module about the management of cancer
risk based on recommendations from the National
Comprehensive Cancer Network [44].
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Figure 1. Examples from the Family Gene Toolkit.
The research team will create tailored messages based on the
linguistic and cultural adaptations of the modules. Tailoring is
a process that fits the message to meet one’s personal needs and
characteristics, rather than targeting group criteria [45,46].
Tailored messages improve whether and how one listens to a
message and its impact on behavior change. Shallow tailoring
involves elements of appearance (eg, female or male mutation
carriers), whereas deep tailoring involves more complex
elements of relevance (eg, coping style). Adaptation of the
Family Gene Toolkit involves elements of both shallow and
deep tailoring based on preintervention assessments of
participants’ characteristics such as sex, affected with cancer
versus cancer-free, and tendency to rely more on a specific
coping style. The research team will use readily available
e-learning products with different tailored messages, multiple
interactions and assessments, and a device-agnostic interface
for the adaptation of the Family Gene Toolkit. Messages will
be developed in English and translated at the eighth-grade
reading level while considering Swiss and Korean legislation,
health insurance policy, cultural values, and national languages.
Swiss and Korean stakeholders will review the content of the
adapted Family Gene Toolkit and identify the required
modifications by providing feedback on word choices,
sensitivity of messages, and appearance. Mini focus groups and
individual interviews with clinicians involved in genetic
consultations will evaluate the prototype of each module and
the tailoring elements. Focus groups with Swiss and Korean
HBOC mutation carriers and relatives will provide suggestions
to enhance the comprehensibility, usefulness, acceptability, and
feasibility of the intervention. Feedback from clinicians and
HBOC families will help in further refining each module and
the tailored messages.
Assessing the usability of the adapted Family Gene Toolkit
involves task-oriented assignments about the most important
functions and features of the website as well as the ease and
user-friendliness of navigation. Participants will think aloud
while navigating each module and complete each task [47].
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They will also evaluate the tailored messages for readability
and comprehension.
Swiss and Korean participants will complete the 5 modules at
their own pace, but within a timeframe of 4 weeks after they
first engage with the platform. The 4-week interval enables
information assimilation and adequate time to reflect and act
based on tailored messages while providing a controlled learning
environment. Feedback will be based on baseline responses,
including tailored advice about improvements that can be made.
Consistent with testing real-world alternatives [48], the
DIALOGUE study will provide a comparison website with
targeted (generic) information. The comparison website will
mimic the structure and functions of an existing website [49].
The adapted Family Gene Toolkit and the comparison website
will be technically implemented in the same system that will
collect baseline and follow-up data, randomize participants,
deliver the intervention and the comparison website, track access
and use of the platform, and provide a user-friendly experience
to participants.
Aim 3: Evaluate Intervention Efficacy on Primary and
Secondary Outcomes
A cluster RCT will evaluate the magnitude of intervention
effects as compared with the comparison website.
Randomization will occur at the family level, that is, after
baseline data collection, the digital health intervention will
randomly assign mutation carriers to either intervention arm,
stratifying for country. Invited relatives will be automatically
directed to the same arm as the mutation carrier. All study
participants will complete a survey at baseline (T1) before the
intervention and again at 2 months (T2) and 6 months (T3) after
the intervention. The 2- and 6-month follow-up time points will
assess the short-term and long-term effects in line with our
previous studies [33,50].
Aim 4: Explore Intervention Translatability
The implementation and dissemination of the adapted Family
Gene Toolkit will be evaluated based on the constructs of the
RE-AIM framework [51] at the individual and organizational
levels.
Settings
The DIALOGUE study involves oncology and genetic testing
centers of the Swiss CASCADE Consortium from 3 linguistic
regions of Switzerland (German-, French-, and Italian-speaking)
and similar settings in Korea, eg, Severance Hospital, Seoul,
and the National Cancer Center, Goyang. Settings ensure
diversity in hospital characteristics (eg, general or advanced
level) and geographic location to increase sample
representativeness and generalizability.
Sample and Sample Size
The DIALOGUE study targets individuals who have been
identified through genetic testing as carrying a BRCA pathogenic
variant (proband) and their blood relatives. Textbox 1 describes
the inclusion criteria for the probands and relatives. Eligible
probands will be females and males (expected female-to-male
ratio=4:1) and their first- and second-degree relatives (parents,
siblings, offspring, aunts, uncles, nieces, nephews, and
grandparents) and their first cousins. Participants may have a
cancer diagnosis (expected breast-to-ovarian cancer ratio=5:1)
or they may be cancer-free. Individuals who tested positive for
a variant of uncertain significance and mutation carriers without
any blood relatives, spouses, and partners are excluded because
cascade genetic testing does not apply to them. We also exclude
individuals who tested positive for a non-BRCA pathogenic
variant because of the current variation in the implementation
of panel testing among the different sites, which will likely
influence the recruitment of participants with non-BRCA
mutations. The study will only include adults because hereditary
cancer risk assessment is not recommended for children. The
study will also exclude vulnerable participants, such as critically
ill patients and those living in nursing homes, to avoid increasing
the subject burden and provide surveillance recommendations
to participants who are not able to follow through the program.
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Textbox 1. Inclusion criteria.
Switzerland
• Probands
• Has tested positive for a BRCA pathogenic variant
• ≥1 first- or second-degree relative or first cousin
• Probands and relatives
• ≥18 years old
• German, French, Italian, and English
• Swiss resident
• Mentally able to provide written consent
• Access to computer, tablet, or smartphone
Korea
• Probands
• Has tested positive for a BRCA pathogenic variant
• ≥1 first- or second-degree relative or first cousin
• Probands and relatives
• ≥19 years old
• Korean and English
• Korean resident
• Mentally able to provide written consent
• Access to computer, tablet, or smartphone
K-CASCADE Cohort
Estimates of sample accessibility follow consultations with the
medical directors of clinical sites and assume average HBOC
prevalence rates of 5% for both countries. There are
approximately 90 new mutation carriers per year from the
clinical centers affiliated with the Swiss CASCADE Consortium.
Data from the Swiss CASCADE cohort indicate that it is feasible
to recruit approximately 50% of the probands from each clinical
site. Each proband is willing to invite an average of 4 relatives,
with a response rate of 50% among relatives. In Korea, with 5
participating hospitals, 540 individuals are expected to enter
the K-CASCADE cohort over 3 years (6 individuals per
month×12 months×3 years×5 hospitals, 50% participation rate).
Intervention Adaptation
A purposeful sample of 20-24 participants (10-12 mutation
carriers and 10-12 relatives) per linguistic region will participate
in individual interviews and/or mini focus groups in each
country. There will be homogeneity within members of each
focus group, but the samples will be diversified in terms of
demographics (eg, sex) and clinical history (eg, affected with
cancer vs cancer-free) among groups. Mini focus groups or
interviews will be conducted with a convenience sample of 6-10
expert clinicians involved in genetic consultation in each
country. Mini focus groups allow more time to share experiences
and encourage greater in-depth information and insights. The
adapted Family Gene Toolkit will be tested for usability and
acceptability with 5 new mutation carriers and/or relatives per
linguistic region [52,53].
Intervention Efficacy
The cluster RCT will invite 114 probands to have a total of 104
evaluable subjects (52 for each website). This sample size would
allow detecting whether using the adapted Family Gene Toolkit
or the comparison website would increase the proportion of
informed relatives by 25% with a statistical power of 80%, a
significance level of 5%, and a dropout rate of 9.6% (11/114).
We estimated the distribution of the proportion of relatives and
dropout rates from our previous studies [14,50]. Less than 10.5%
(12/114) of potential participants have no relatives, and less
than 10.5% (12/114) have no access to a computer, tablet, or
smartphone, making them ineligible for the study. We expect
to recruit and retain the final sample of 114 probands over 18
months.
Intervention Translatability
This step involves assessing the potential for implementing the
adapted Family Gene Toolkit in real-world conditions. RE-AIM
dimensions will be assessed from participating and
nonparticipating mutation carriers, relatives, and providers
throughout the study.
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The opportunity to participate in the K-CASCADE cohort will
be advertised through the KOHBRA network, the Ovarian
Cancer and Genetics study group, and other clinical sites.
Recruitment procedures for Korean probands and relatives will
follow steps and procedures similar to those outlined for the
Swiss CASCADE cohort [14]. In short, index cases (first person
in the family with the pathogenic variant) identified in
participating centers will be invited to participate in the study
by collaborating clinicians and through patient advertisements
posted in the clinics. Potential participants will also be able to
view information on the study website. Individuals carrying a
BRCA pathogenic variant, and if they have at least one eligible
relative based on pedigree data, will meet study recruiters to
ask questions and provide written consent. To alleviate ethical
concerns associated with contacting blood relatives without
their explicit consent, the K-CASCADE cohort will approach
them through probands, targeting only relatives the proband is
willing to contact. This recruitment method is used by the Swiss
CASCADE cohort and in previous family-based studies with
very good recruitment outcomes [39,54]. Relatives agreeing to
participate will also provide written consent. In the consent
form, probands and relatives will indicate their willingness to
invite additional relatives to the K-CASCADE, be contacted
once a year for 5 years and provide updated information about
their health, participate in a focus group or individual interview
for the adaptation of the Family Gene Toolkit in Korean, and
participate in an RCT for testing the effects of the adapted
Family Gene Toolkit. Probands and relatives may participate
in all or some of the study steps previously described.
Probands and relatives will provide baseline assessments via a
URL link to the digital health intervention and a unique
passcode. A second prompt will be sent 2 weeks later. If there
is no response to the second contact, study recruiters will contact
the participants by phone. Relatives will also provide written
consent, and they will receive a URL with a unique passcode.
The Swiss CASCADE platform will facilitate data collection
in both countries to maintain the consistency and accuracy of
data entry, data management, and analyses. Korean respondents
will log on as K-CASCADE participants to provide survey data.
Intervention Adaptation
Participants will be recruited through the Swiss CASCADE
cohort and through flyers posted in the affiliated Korean
institutions and clinics. After obtaining consent, focus groups
or individual interviews will be organized at an easily accessible
site and in participants’ language. Focus groups will be coded
by 2 members of the team in each country and linguistic region
and will be audiotaped with participants’ explicit consent.
Participants will be asked to think aloud while viewing
electronic mockups of the intervention and while navigating a
final version of the digital health intervention. The latter sessions
will be videotaped.
Clinicians involved in genetic consultations will be identified
through the CASCADE Consortium in Switzerland; through
the Schweizerischen Arbeitsgemeinschaft für Klinische
Krebsforschung, Network for Cancer Predisposition Testing
and Counseling in Switzerland; and through the KOHBRA
network in Korea. They will be recruited via email and/or
invitation letters and will also provide consent. Semistructured
exploratory questions will elicit their opinions on structural
barriers to HBOC cascade genetic testing. At a later stage, they
will also view a nearly final version of the digital health
intervention and will provide feedback. Sessions will be
audiotaped and videotaped with clinicians’ consent.
Intervention Efficacy
After they complete the baseline questionnaires (T1), probands
(index case) in both countries who agree to participate in an
RCT and test the effects of the adapted Family Gene Toolkit
will be emailed a unique URL link and passcode allowing them
access to the digital health intervention. Furthermore, they will
be able to log in and review the intervention modules multiple
times using the same URL link and passcode. The system will
randomize participants in a 1:1 ratio to either the digital health
intervention or the comparison website. Stratification by country
(Switzerland vs Korea) will be facilitated with different URL
links for participants from each country. Participants will receive
weekly email or text alerts, encouraging them to visit the website
and complete viewing of the contents of the digital health
intervention within 4 weeks. They will also receive email or
text alerts to complete a knowledge quiz, an exercise for value
clarification related to genetic testing, and a family
communication rubric that will be included in the content of
the different modules. Participants randomized to the
comparison website will receive 1 email alert 2 weeks after they
engage with the website. Relatives will be allocated to the same
study arm as the respective proband and will also receive a URL
link and a unique passcode. Relatives will first be asked to
complete a consent form and then to complete the baseline
survey, after which they will have access to either the adapted
Family Gene Toolkit or the comparison.
Primary and secondary outcomes will be assessed at 2 months
(T2) and 6 months (T3) after the intervention. We selected the
2- and 6-month follow-up time points to measure the short-term
and long-term intervention effects, in line with our previous
studies [33,50]. To minimize the attrition rate, if a response has
not been received within 2 weeks from the time participants
receive the URL link to the follow-up survey, then the study
personnel will make 3 attempts to contact them by email or
phone and encourage them to complete the survey.
Measures and Outcomes
K-CASCADE
The core questions of the Swiss CASCADE cohort [14]
constitute the basic measurements for the K-CASCADE.
Instruments are purchased (if not available for free) and will be
translated into Korean (if not available) following the World
Health Organization’s translation guidelines. The baseline
survey covers cancer diagnoses and surveillance, use of and
experience with genetic testing (for testers and nontesters),
communication with health care providers, and satisfaction with
cancer genetic services. It assesses information about
prophylactic surgeries; epidemiological data about personal,
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reproductive, and family history of breast and ovarian cancer;
and modifiable lifestyle risk factors (smoking, drinking, physical
activity, etc). The baseline survey also assesses demographic
characteristics and psychosocial variables, for example, the fear
of cancer recurrence and self-efficacy to use services, which
constitute the basis for creating the tailored messages provided
by the adapted Family Gene Toolkit. These instruments are
listed in Table 1. The Korean survey will be pilot tested with
10 study participants for comprehension and accuracy.





✓b——aSelf-report [55]Demographics, personal, and family
cancer history
Tailoring variables
✓N/AN/AcSelf-reportDegree of relationship between
proband-relatives (eg, first de-
gree)
✓0.91.93Concerns About Recurrence Scale [56], 4 items,
7-point Likert scale
Fear of cancer recurrence (for
patients)
✓0.71.80Self-efficacy–HBOCd-related cancer [57], 14
items, 7-point Likert scale
Self-efficacy dealing with cancer
(for patients)
✓N/AN/A1 item, 7-point Likert scaleSelf-efficacy using genetic ser-
vices
✓0.83.86Family Support in Illness [58], 10 items, 7-point
Likert scale
Family support
✓0.82.90Family Hardness Index [59], 20 items, 7-point
Likert scale
Family hardiness
✓—.81Multidimensional Impact of Cancer Risk Assess-
ment [60], 19 items, 7-point Likert scale
Satisfaction with genetic counsel-
ing (for tested individuals)
✓N/AN/ABarriers and facilitators for genetic services [61],
11 items, multiple choice
Barriers and facilitators for genet-
ic services
aNot available.
bThe variable will be assessed at the specific time frame.
cN/A: not applicable.
dHBOC: hereditary breast and ovarian cancer.
Intervention Adaptation
A trained moderator will ask focus group participants to answer
semistructured exploratory questions designed to elicit their
opinions on the most pressing issues for family communication,
using appropriate probe questions to explore potential cultural
interpretations. The interview guide explores issues around
family communication that took place during the genetic
consultation, decision making related to the disclosure of test
results to relatives, and attitudes toward using digital health
platforms. Participants will also rate their satisfaction with the
content, format, and appearance of the website. Assessing
intervention feasibility also involves assessing the number of
modules accessed, time spent on each module, and the utilization
of links, which are automatically recorded on the website.
Intervention Efficacy
Data to evaluate the magnitude of intervention effects will be
assessed using the instruments listed in Table 2. These have
strong psychometric properties and have been used in previous
studies on patients with cancer. Most of these instruments have
been translated into and validated in German, French, and Italian
and will be translated into and validated in Korean. Primary
and secondary outcomes are assessed at the 2-month and
6-month follow-up surveys. Satisfaction with the intervention
and acceptability will be assessed at the 2-month follow-up with
questions about intervention usefulness, ease of use, clarity,
appropriate length, level of detail, relevance, and interest with
a 7-item survey (Likert scale ranging from 1=low to 7=high)
[62,63].
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✓✓bN/AN/AaWebsite dataProportion of informed relatives
✓✓—c.86Informing Relatives Inventory [64], 68 items, 7-
point Likert scale
Intention to inform relatives
✓✓N/AN/A1 item, 7-point Likert scaleIntention for genetic testing
(untested relatives)
Secondary outcomes
✓✓—.86Profile of Mood States [65], 37 items, 7-point
Likert scale
Psychological distress
✓✓0.85.89Risk Factor Knowledge Index [39], 17 items, true,
false, and do not know
Genetic literacy—genetic affinity
✓✓0.81.82Breast Cancer Genetics Index [66], 12 items, true,
false, and do not know
Genetic literacy—cancer genetics
✓✓0.78.81Brief Cope [67], 25 items, 7-point Likert scaleCoping with stressful events
✓✓—.96Decisional Conflict Scale-HBOCd Genetic Testing
[68], 16 items, 7-point Likert scale
Decision making—untested indi-
viduals










bThe variable will be assessed at the specific time frame.
cNot available.
dHBOC: hereditary breast and ovarian cancer.
Intervention Translatability
Textbox 2 outlines RE-AIM outcomes to be assessed, which
will help in evaluating the potential for a broader implementation
and dissemination of the digital health intervention.
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Textbox 2. Reach, effectiveness, adoption, implementation, and maintenance outcomes assessed in the study.
Reach (individual)
• Response rate of mutation carriers and relatives
• Number of probands and relatives accessing the website
• Demographic, linguistic characteristics, and region
• Response rate to K-CASCADE (Korean–Cancer Predisposition Cascade Genetic Testing)
Effectiveness (individual)
• Assess the number of times participants accessed each module
• Assess the number of relative invites initiated through the website
• Evaluate the acceptability, interest, usefulness, level of detail, relevance, and satisfaction follow-up survey
Adoption (setting, staff, and organization)
• Number of clinicians and new settings willing to participate in the study
• Diversity (geographic, linguistic, etc) in participating settings
Implementation (setting, staff, and organization)
• Monitor referrals of mutation carriers from different clinical sites
• Evaluate the cost for adapting modules for other hereditary cancer syndromes (eg, Lynch syndrome)
Maintenance (individual and setting)
• Assess resources needed to maintain the website
• Assess the number of visits per month per year
Data Management and Data Analyses
K-CASCADE Cohort
Korean participants’ data entered in the Swiss CASCADE
platform will be available for descriptive and comparative
analyses, using epidemiological and psychosocial data along
with coded and nonidentified clinical data. Existing clinical
data from Severance Hospital, stored in the Clinical Research
Analysis Portal, will also be accessed for participants who
provide additional consent. At year 4, the accrued data from
Korean women will be used in conjunction with clinical data
for comparative analyses with the Swiss CASCADE cohort.
Intervention Adaptation
The mini focus groups or interviews with HBOC families and
clinicians will be audiorecorded with participants’ consent and
transcribed verbatim, using codes to protect individual
identification. Transcripts will be reviewed by the research team,
and content will be analyzed using an iterative process of
reading transcripts, coding, and comparing the data to identify
salient themes. Two members of the research team in each
country will also review the videotapes obtained from usability
testing and the think aloud protocol. They will confirm that
there are no functional errors on the website, color schemes and
graphical images are well received, participants can navigate
through various sections of the website with ease, the layout
accurately conveys information, and the program works as
expected. Data regarding acceptability will be analyzed using
descriptive statistics.
Intervention Efficacy
The efficacy cluster RCT will use pre- and postintervention
data from baseline (T1) and follow-up (T2 and T3) surveys. Data
values will be checked for validity (within the appropriate range)
using histograms and box plots and corrected whenever possible.
Many items are a part of multi-item scales and are anticipated
to correlate with each other. Scales will be tested for internal
consistency reliability with Swiss and Korean participants using
principal component analysis and Cronbach α coefficients.
Scales with Cronbach α values of .71 and higher will be used.
Multiple imputation or other techniques will address missing
data if they exceed 5% of observations and if they are less than
25% for each specific scale. Data from participants who
withdraw will be kept to ensure internal validity.
Primary outcomes will be calculated with the
Wilcoxon-Mann-Whitney test to compare the proportions of
informed relatives per study arm. Other primary and secondary
outcomes and metadata from the automatic recording of website
activity will be analyzed using descriptive statistics. Descriptive
analyses will include calculating the means and frequencies of
key variables and subject descriptors (eg, genetic testing). This
will include tabulating counts and frequencies of variables,
including demographics and personal cancer history. Bivariate
analyses (using the chi-square test for differences in proportions
and t test for differences in means) will assess the associations
between demographic factors and clinical characteristics. The
following comparisons will be made: between probands and
relatives, between men and women, between patients with
cancer and cancer-free individuals, between participants with
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children and those with no children, between different age
groups, and between patients with different cancer diagnoses.
A detailed methodology for summaries and statistical analyses
will be documented in a statistical analysis plan. This plan will
be finalized before database closure and will be under version
control at the Clinical Trial Unit, University Hospital Basel. All
analyses will be conducted using the statistical software R [71],
using two-sided statistical tests and confidence intervals with
confidence levels α=5% and (100%−α)=95%, respectively.
Deviations from planned analyses are not foreseen. The study
statistician will review and approve any deviations from the
original statistical plan.
Intervention Translatability
Data exploring the RE-AIM of the digital health intervention
will be analyzed using qualitative and quantitative methods.
Narrative data obtained from mini-interviews will be
audiorecorded, transcribed verbatim, and analyzed for common
themes. Descriptive analyses will include calculating the means
and frequencies of the key variables and subject descriptors.
Bivariate analyses (chi-square test for differences in proportions
and t test for differences in means) will compare key variables
between participants and nonparticipants.
Results
The DIALOGUE study, including the development of the
K-CASCADE cohort in Korea, was funded in October 2019. It
is projected that data collection will be completed by January
2023, and results will be published in fall 2023.
Discussion
Principal Findings
The need to enhance family communication around HBOC has
been documented in the literature since mid-2000 [72-74],
followed approximately 10 years later by scientific calls to
enhance cancer predisposition cascade genetic testing [75-77].
The DIALOGUE study is a resource-effective international
research platform that proposes building a tailored, interactive
website to reach a large number of HBOC families and enhance
cancer predisposition cascade genetic screening, presumably
requiring only a fraction of the cost and required clinician time
compared with previous approaches. Developing the
K-CASCADE cohort will link together the expertise of an
eminent network of HBOC scholars and clinicians that will
benefit both countries and serve as a model for potential
expansion to other countries and in other language contexts.
The cross-cultural adaptation of the Family Gene Toolkit will
help explore the similarities and differences in communication
practices among HBOC families in the Swiss and Korean
contexts, potentially providing important information about the
Korean and Swiss contexts that affect HBOC discourse [78].
This comparison will also reveal context-specific characteristics
regarding the influence of the health care system, insurance
coverage, and socioeconomic aspects on the application of
genetic knowledge that can provide useful information for
adapting other digital health solutions within the Swiss and
Korean contexts. The goal of the adapted Family Gene Toolkit
is to attend to the needs of diverse families, including the
function of different members, and cultural and linguistic
backgrounds. It is thus important to consider digital health
technologies as sociocultural products with a need for an
adaptation to specific local contexts and a critical reflection
about how they may affect local perceptions of illness [78]. The
final product will likely be more cost-effective and will expedite
scaling-up, dissemination, and implementation, given the
existing strong clinical partnerships within each country.
Conclusions
The adaptation and implementation of culturally sensitive,
digitally based health interventions that enhance the
understanding of genetic cancer risk are extremely timely and
relevant, given the expansion of genetic testing technology, the
falling costs of genetic testing, and the increased pressure for
the integration of genetic knowledge in routine clinical care.
Genetic testing for hereditary susceptibility to disease has
received increasing attention among the health care community
and at the individual, familial, and international levels. The
DIALOGUE study will contribute to the development of
high-quality comprehensive support systems that enhance the
counseling process and facilitate informed decision making by
minimizing conflict and distress and making resources available
in culturally appropriate ways. Ultimately, the study contributes
to a broader dissemination of genetic information and helps in
expanding the public health understanding of the impact of new
technologies on risk stratification and disease management.
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